Nothing Special   »   [go: up one dir, main page]

BR112012022552A8 - uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos - Google Patents

uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos

Info

Publication number
BR112012022552A8
BR112012022552A8 BR112012022552A BR112012022552A BR112012022552A8 BR 112012022552 A8 BR112012022552 A8 BR 112012022552A8 BR 112012022552 A BR112012022552 A BR 112012022552A BR 112012022552 A BR112012022552 A BR 112012022552A BR 112012022552 A8 BR112012022552 A8 BR 112012022552A8
Authority
BR
Brazil
Prior art keywords
fenoterol
treatment
analogs
gliobastomas
astrocytomas
Prior art date
Application number
BR112012022552A
Other languages
English (en)
Other versions
BR112012022552A2 (pt
Inventor
W Wainer Irving
Robert Toll Lawrence
Arenas Jimenez Lucita
Bernier Michael
Original Assignee
Stanford Res Inst Int
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Res Inst Int, Us Health filed Critical Stanford Res Inst Int
Publication of BR112012022552A2 publication Critical patent/BR112012022552A2/pt
Publication of BR112012022552A8 publication Critical patent/BR112012022552A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas. a presente invenção refere-se à descoberta do uso de fenoterol e análogos de (r,r)- e (r,s)-fenoterol no tratamento de um tumor que expressa um receptor-<225>~ 2~ adrenérgico, tal como tumor cerebral primário, incluindo glioblastoma ou astrocitoma que expressa um receptor-<225>~ 2~ adrenérgico. em um exemplo, o método inclui administrar um análogo de fenoterol específico ou uma combinação destes para reduzir um ou mais sintomas associados ao tumor, tratando assim o tumor do paciente.
BR112012022552A 2010-03-10 2011-03-10 uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos BR112012022552A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31264210P 2010-03-10 2010-03-10
PCT/US2011/027988 WO2011112867A1 (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Publications (2)

Publication Number Publication Date
BR112012022552A2 BR112012022552A2 (pt) 2016-08-30
BR112012022552A8 true BR112012022552A8 (pt) 2017-12-05

Family

ID=43858307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022552A BR112012022552A8 (pt) 2010-03-10 2011-03-10 uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos

Country Status (7)

Country Link
US (4) US9492405B2 (pt)
EP (1) EP2544676B1 (pt)
JP (1) JP5837890B2 (pt)
AU (2) AU2011224241B2 (pt)
BR (1) BR112012022552A8 (pt)
CA (1) CA2791702C (pt)
WO (1) WO2011112867A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2854855B1 (en) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
EP3125877A4 (en) * 2014-04-03 2017-11-22 Mitchell Woods Pharmaceuticals, Inc. Methods of treating melanoma
CA2944726A1 (en) * 2014-04-03 2015-10-08 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
KR101585619B1 (ko) * 2014-11-20 2016-01-15 주식회사 아모텍 감전보호소자 및 이를 구비한 휴대용 전자장치
US20180042867A1 (en) * 2015-03-06 2018-02-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
WO2017059268A1 (en) * 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
AU2016341109A1 (en) * 2015-10-18 2018-06-07 Onco Therapies Llc Compositions and methods of regulating cancer related disorders and diseases
EP3506926A4 (en) * 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
GB201714736D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
CN114456078B (zh) * 2022-01-19 2022-09-16 汉瑞药业(荆门)有限公司 一种(r)-n-苄基-1-(4-甲氧基苯基)丙-2-胺的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL296701A (pt)
SE354279B (pt) 1969-06-13 1973-03-05 Draco Ab
CH564509A5 (pt) 1969-12-12 1975-07-31 Boehringer Sohn Ingelheim
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
DE2010883A1 (de) 1970-03-07 1971-09-23 Troponwerke Dinklage & Co, 5000 Köln-Mülheim Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung
AT308139B (de) 1970-07-27 1973-06-25 Degussa Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen
IT1044214B (it) 1971-04-22 1980-03-20 Zambeletti Spa L 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione
JPS532194B2 (pt) 1973-08-10 1978-01-26
US6866839B2 (en) 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US5352806A (en) 1992-04-17 1994-10-04 Abbott Laboratories Taxol derivatives
AU4408897A (en) 1996-07-05 1998-02-02 E.C. Pesterfield Associates, Inc. Method of treating retinal ischemia and glaucoma, using optically pure r- or rr- isomers of adrenergic beta-2 agonists
US6015837A (en) 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
WO1999016430A1 (en) 1997-09-30 1999-04-08 E.C. Pesterfield Associates, Inc. Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
AU6167599A (en) 1998-09-30 2000-04-17 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of a beta2 adrenergic receptor agonist in the treatment of cardiovascular disease
AR030188A1 (es) 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
PT1506203E (pt) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
US20050107417A1 (en) 2003-07-28 2005-05-19 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
DE602004016547D1 (de) 2003-11-03 2008-10-23 Myogen Inc 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
EP1737447A1 (en) 2004-03-22 2007-01-03 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
CA2576255A1 (en) 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
WO2006074897A1 (en) 2005-01-11 2006-07-20 Glaxo Group Limited Cinnamate salts of a beta-2 adrenergic agonist
KR101378067B1 (ko) * 2006-08-10 2014-04-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 （ｒ,ｒ）―페노테롤 및 （ｒ,ｒ）―또는 （ｒ,ｓ）―페노테롤 유사체의 제조방법 및 이의 울혈성 심부전증 치료를 위한 용도
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
EP2207537B1 (en) 2007-10-02 2017-06-14 Fremont Group Ltd Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alpha-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
WO2011079279A2 (en) * 2009-12-23 2011-06-30 Board Of Trustees Of The University Of Illinois Nanoconjugates and nanoconjugate formulations

Also Published As

Publication number Publication date
US10925840B2 (en) 2021-02-23
EP2544676B1 (en) 2018-09-19
WO2011112867A1 (en) 2011-09-15
US9492405B2 (en) 2016-11-15
US20190008802A1 (en) 2019-01-10
CA2791702A1 (en) 2011-09-15
US10130594B2 (en) 2018-11-20
US20130005799A1 (en) 2013-01-03
BR112012022552A2 (pt) 2016-08-30
WO2011112867A8 (en) 2012-09-27
AU2014210656A1 (en) 2014-08-28
US20200197332A1 (en) 2020-06-25
AU2011224241A1 (en) 2012-09-20
US20170007556A1 (en) 2017-01-12
AU2014210656B2 (en) 2016-03-17
JP5837890B2 (ja) 2015-12-24
US10617654B2 (en) 2020-04-14
AU2011224241B2 (en) 2014-05-08
JP2013522230A (ja) 2013-06-13
EP2544676A1 (en) 2013-01-16
CA2791702C (en) 2018-05-29

Similar Documents

Publication Publication Date Title
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
IN2015DN03219A (pt)
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
BR112015008480A2 (pt) compostos de benzeno substituído
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112012021275A2 (pt) composição, formulação, e, uso de uma formulação.
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112012016783A2 (pt) &#34;usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia&#34;
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112016016356A2 (pt) Imunoterapia baseada em lipossomas
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
CL2010001174A1 (es) Uso de espironolactona, sus polimorfos, hidratos o solvatos para preparar un medicamento util para prevenir y/o tratar la esclerosis muiltiple.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]